First, although we addressed the discernible DTI parameters and FAB performance between the patients with SIVD and those with AD during the early stage, we lacked data related to the pathophysiological biomarkers of AD (i.e., cerebrospinal fluid tau protein and Abeta42). The gene discussed is MAPT; the disease is Alzheimer disease.